Research Network: N-Power Medicine Acquires Syapse for Oncology
N-Power Medicine, a leader in transforming the clinical trial process, has announced the acquisition of Syapse Holdings Inc. (“Syapse”), a trailblazer in precision medicine solutions for community cancer centers. By integrating Syapse into N-Power Medicine, the company strengthens its existing infrastructure with Syapse’s vast network of over 1,000 oncologists, as well as its data systems, technology stack, and dedicated team.
N-Power Medicine collaborates with community oncologists through its proprietary Kaleido Registry and AI-powered point-of-care platform. This system, which is complemented by both virtual and on-site support, aims to optimize clinical research and patient care workflows. The acquisition will significantly expand N-Power’s reach, creating the largest community-based prospective clinical research network. Through this network, every patient will have research-ready data and documentation integrated into their routine care, making it easier for them to participate in clinical trials.
This move addresses one of the key challenges in oncology: the limited access to clinical trials in community settings. More than 80% of U.S. cancer patients—especially those from diverse and underrepresented populations—receive care in community settings but have historically faced barriers to participating in clinical trials. By integrating Syapse’s extensive network, N-Power Medicine aims to break down these barriers, enhancing patient access and helping bridge gaps in cancer care.
The acquisition will also enhance N-Power’s current services for its growing list of pharmaceutical clients, including Merck. This partnership, already involving multiple clinical trials, will now have greater access to a broader and more diverse group of community-based cancer patients for enrollment. The expanded network’s scale will enable more efficient and rigorous generation of prospective external controls, which will facilitate smaller, faster clinical trials. This new capacity will significantly streamline the drug development process, reducing the need for traditional randomized trials.
Dr. Mark Lee, M.D., Ph.D., Co-Founder and CEO of N-Power Medicine, emphasized the importance of the acquisition. “Integrating Syapse into N-Power underscores our commitment to accelerating drug development and increasing the likelihood of success by seamlessly incorporating clinical research into everyday oncologist practices and cancer patient care,” said Lee. “With this expansion, we are responding to the needs of our pharmaceutical partners by enabling broader access to clinical trials for community oncologists and patients than ever before. This also creates a unique platform for generating prospective external controls, reducing the reliance on randomized trials.”
Syapse’s CEO, Michael Mentesana, also commented on the acquisition, noting the transformative potential of the partnership. “Syapse joining N-Power marks a significant step forward in our shared mission to revolutionize community-based cancer care,” said Mentesana. “By leveraging Syapse’s existing infrastructure and combining it with N-Power’s AI-enabled, ‘human-in-the-loop’ approach, we can greatly increase patient access to clinical trials and accelerate the delivery of life-saving innovations for those in community settings.”
The acquisition of Syapse was finalized on December 30, 2024, through a stock-for-stock exchange. Innovatus Capital Partners LLC, Syapse’s lead institutional investor, has joined N-Power’s existing investors, including Merck’s Global Health Innovation Fund (GHI) and a U.S.-based healthcare-focused investor, in providing ongoing funding for the combined company’s future growth and vision.
This strategic acquisition enables N-Power to continue expanding its impact on oncology research, offering significant advantages for both pharmaceutical companies and patients. The combined company’s platform will not only boost the scale of clinical trial participation but also ensure more diverse and inclusive representation in cancer research. By transforming community oncology into a research-driven hub, N-Power aims to speed up the development of innovative therapies and ensure they reach patients in need as quickly as possible.
About N-Power Medicine
N-Power Medicine is a clinical research and drug development platform focused on addressing critical barriers to clinical trial participation. Founded in 2021, the company is dedicated to accelerating oncology drug development by integrating technology and trained personnel into routine care at cancer sites. N-Power aims to unlock the full potential of real-time data to bring new cancer therapies to patients more efficiently, ultimately helping to speed up the process of delivering life-saving innovations.
About Syapse
Syapse is a precision medicine company that has been at the forefront of transforming cancer care through data-driven solutions. The company provides tools and technologies designed to enhance the ability of community health systems to offer personalized treatments for cancer patients. With a focus on improving patient outcomes and expanding access to clinical trials, Syapse has built a robust platform for oncology research in the community setting.
The acquisition by N-Power Medicine represents a critical step in realizing a future where community oncology plays a central role in advancing clinical research and improving cancer treatment outcomes.
